Related Experiment Video
Updated: May 13, 2026
05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
Amyloid imaging for Alzheimer's disease
1Stanford University School of Medicine, Stanford Center for Memory Disorders , Department of Neurology and Neurological Sciences , 300 Pasteur Drive, Room A343, MC5235, Stanford, W CA 94305-5235 , USA +1 650 723 2078 ; +1 650 723 7434 ; kerchner@stanford.edu.
Expert Opinion on Medical Diagnostics
|March 15, 2013
Summary
Amyloid imaging accurately detects fibrillar beta-amyloid (Aβ) pathology in Alzheimer's disease (AD) brains. Further research is needed to fully understand Aβ's role in AD before maximizing amyloid imaging's clinical potential.
Area of Science:
- Neurology
- Radiochemistry
- Biomarker Discovery
Background:
- Biomarkers are crucial for early Alzheimer's disease (AD) diagnosis and monitoring therapeutic efficacy.
- Amyloid imaging provides non-invasive visualization of fibrillar beta-amyloid (Aβ) pathology in living humans.
- Emerging diagnostic criteria for AD increasingly incorporate amyloid imaging technologies.
Purpose of the Study:
- To review current amyloid imaging tracers for Alzheimer's disease (AD).
- To discuss the relationship between Aβ pathology and AD.
- To explore the clinical utility of amyloid imaging in diagnosis and clinical trials.
Main Methods:
- Review of literature on amyloid imaging tracers, including (11)C-Pittsburgh Compound B and (18)F-labeled agents.
- Discussion of apolipoprotein E genotyping and cerebrospinal fluid Aβ levels in conjunction with amyloid imaging.
- Analysis of the role of amyloid imaging in patient selection and outcome monitoring for clinical trials.
Main Results:
- Amyloid imaging tracers effectively detect fibrillar Aβ pathology.
- A direct correlation between Aβ detection and true AD pathology requires further elucidation.
- Amyloid imaging shows potential as a diagnostic tool and for clinical trial applications.
Conclusions:
- Amyloid imaging reliably visualizes fibrillar Aβ pathology in the brain.
- Fundamental questions regarding the role of Aβ in AD pathogenesis remain.
- The full clinical potential of amyloid imaging is contingent upon resolving these fundamental questions.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:25Imaging Studies II: Positron Emission Tomography and Scintigraphy
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
Fundamental Principles of PET